Shamburg News · 8-K filed Oct 30, 2026, 8:02 AM EDT

Azenta Enters Elegen License and Supply Agreements and Acquires SynPlexity

AZTA · Azenta, Inc.

  • Material agreement
  • Acquisition
  • Reg FD disclosure
  • Other event
  • Materiality: high

On October 28, 2026, Azenta, Inc. entered into a License Agreement and a Master Services and Supply Agreement with Elegen Corp. granting an exclusive, royalty-free license to certain gene synthesis products for its GENEWIZ business, with aggregate capital deployment expected at approximately $32 million to $71 million. The same day, Azenta acquired all outstanding capital stock of SynPlexity Inc., a DNA assembly technology company, under a Stock Purchase Agreement that closed concurrently with signing. The Company issued a press release on October 30, 2026, announcing the transactions, furnished as Exhibit 99.1.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 7.01, 8.01, 9.01, accession 0001628280-26-068443.

Written from the filing by Shamburg Markets. Figures are as reported by the company.